Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs BONTRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Relief of symptoms associated with seasonal or perennial allergic rhinitis,Relief of nasal congestion,Symptomatic relief of upper respiratory tract infections
FDA-approved for management of obesity as a short-term adjunct (few weeks) in a regimen of weight reduction based on caloric restriction, exercise, and behavior modification. Off-label uses are not well documented due to limited evidence.
1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.
BONTRIL 50 mg orally once daily, with or without food.
Dexbrompheniramine: terminal elimination half-life is approximately 12-25 hours in adults. Pseudophedrine: terminal elimination half-life is about 5-8 hours in adults with normal renal function; it is prolonged in patients with renal impairment.
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Dexbrompheniramine is primarily metabolized by CYP3A4 and CYP2D6. Pseudoephedrine is partially metabolized by N-demethylation and oxidative deamination, with about 43-96% excreted unchanged in urine.
Phendimetrazine is extensively metabolized in the liver, primarily via N-demethylation to its active metabolite phenmetrazine. Minor pathways include hydroxylation and conjugation. Cytochrome P450 enzymes are involved, though specific isoforms are not fully characterized.
Dexbrompheniramine and its metabolites are primarily excreted renally (approximately 80-85% of a dose as unchanged drug and metabolites). Pseudophedrine is largely excreted unchanged in urine (70-90%) via glomerular filtration and tubular secretion; the remainder is hepatically metabolized. Biliary/fecal elimination is minimal (<5%).
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Dexbrompheniramine: approximately 90% bound to plasma proteins. Pseudophedrine: negligible protein binding (<10%).
85-90% bound to albumin and alpha-1-acid glycoprotein.
Dexbrompheniramine: Vd is approximately 3-5 L/kg, indicating extensive tissue distribution. Pseudophedrine: Vd is approximately 2.5-3.5 L/kg.
3-5 L/kg; indicates extensive tissue distribution.
Both components are well absorbed orally. Dexbrompheniramine: oral bioavailability is approximately 60-80%. Pseudophedrine: oral bioavailability is about 90-100%.
Oral: 70-80% (first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: extend interval to every 12-24 hours; GFR <30 m L/min: contraindicated due to risk of accumulation.
GFR >60 m L/min: no adjustment. GFR 30-60 m L/min: reduce dose to 25 mg once daily. GFR <30 m L/min: use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 25 mg once daily. Child-Pugh Class C: use is contraindicated.
Not recommended for children under 12 years; for ages 12+: same as adult dosing.
Weight-based: 1 mg/kg orally once daily, with a maximum of 50 mg. Not recommended for children weighing less than 10 kg.
Start at lowest effective dose (e.g., 1 tablet daily) due to increased sensitivity to anticholinergic effects and risk of confusion; monitor for urinary retention and hypertension.
Start at 25 mg orally once daily; may increase to 50 mg after 2 weeks if tolerated and renal function is adequate (Cr Cl >60 m L/min).
None.
None
Cardiovascular effects: hypertension, palpitations, arrhythmias; use cautiously in cardiovascular disease,CNS stimulation: nervousness, dizziness, insomnia; avoid in severe hypertension or coronary artery disease,Anticholinergic effects: urinary retention, blurred vision; caution in glaucoma or prostatic hypertrophy,Drug interactions: MAO inhibitors, sympathomimetics, antihypertensives
Risk of abuse, dependence, and tolerance; monitor for signs of addiction.,May cause serious cardiovascular events including pulmonary hypertension and valvular heart disease, especially with long-term use.,May impair ability to drive or operate machinery due to dizziness or blurred vision.,Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse.,Concomitant use with other sympathomimetics or MAO inhibitors can cause hypertensive crisis.,Not recommended for use in patients with a history of epilepsy or those taking other anorectic agents.
Hypersensitivity to any component,Severe hypertension or coronary artery disease,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Narrow-angle glaucoma,Urinary retention,Severe hepatic or renal impairment
Known hypersensitivity to phendimetrazine or any component of the formulation.,History of cardiovascular disease including coronary artery disease, arrhythmias, or congestive heart failure.,Hypertension (moderate to severe).,Hyperthyroidism.,Glaucoma.,History of drug abuse or alcoholism.,Concurrent use of monoamine oxidase inhibitors or within 14 days of such use.,Pregnancy and breastfeeding.,Agitated states.,History of seizure disorders.
Avoid high-tyramine foods (e.g., aged cheese, cured meats, fermented products) if taking MAOIs concurrently. Pseudoephedrine's pressor effect may be enhanced by caffeine; limit caffeinated beverages.
Avoid high-fat meals as they may delay absorption of oral formulations. No specific food-drug interactions known; however, anticholinergic effects may be exacerbated by alcohol.
First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine blood flow and cause fetal tachycardia.
BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression if used near term.
Probable compatibility (American Academy of Pediatrics rating). Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~3.3); may cause irritability and sleep disruption in infants. Dexbrompheniramine may suppress lactation. Consider using alternatives with lower risk.
No data available on excretion into human breast milk. M/P ratio unknown. Due to potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during BONTRIL therapy.
No specific adjustments recommended. However, decreased gastrointestinal motility and increased plasma volume may alter absorption and distribution. Monitor clinical response.
No dose adjustment required for pregnancy. However, due to teratogenicity, BONTRIL should be discontinued before conception or as soon as pregnancy is diagnosed.
Dexbrompheniramine is an alkylamine antihistamine with sedative effects; pseudoephedrine is a sympathomimetic decongestant. Avoid in severe hypertension, coronary artery disease, or MAOI use. Monitor for CNS stimulation (insomnia, nervousness) from pseudoephedrine. Antihistamines may exacerbate urinary retention in BPH or narrow-angle glaucoma. Combination therapy is common in OTC cold products.
BONTRIL (hyoscyamine) is an anticholinergic used for GI spasms; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Onset of action is 2-3 minutes IV; monitor for heat stroke in high ambient temperatures due to decreased sweating.
Take with food or milk to reduce stomach upset.,Avoid alcohol and other CNS depressants due to additive sedation.,Do not crush or chew extended-release formulations.,Discontinue and consult prescriber if palpitations, dizziness, or tremor occur.,Not recommended for children under 6 years without prescriber approval.,Use caution when driving or operating machinery until response is known.
Do not drive or operate machinery until you know how this medication affects you, as it may cause dizziness or blurred vision.,Avoid alcohol and other CNS depressants as they may increase sedation.,Report immediately if you experience eye pain, difficulty urinating, or rapid heartbeat.,Use caution in hot weather; this drug reduces sweating and increases risk of heat stroke.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Dexbrompheniramine, a first-generation antihistamine with anticholinergic and sedative properties, when co-administered with guanfacine, an alpha-2 adrenergic agonist used for hypertension or ADHD, can result in additive central nervous system depression. This may lead to enhanced sedation, dizziness, impaired cognitive function, and increased risk of falls, particularly in older adults or those with compromised liver function."
"Quazepam, a benzodiazepine, and dexbrompheniramine, a first-generation antihistamine, both exhibit central nervous system (CNS) depressant effects. Their combined use can lead to additive sedation, psychomotor impairment, and respiratory depression, increasing the risk of falls, cognitive dysfunction, and excessive drowsiness. This interaction is particularly concerning in elderly patients or those with compromised respiratory function."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE vs BONTRIL, answered by our medical review team.
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is a Sympathomimetic that works by Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. BONTRIL is a Sympathomimetic Anorectic that works by Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and BONTRIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is: 1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.. The standard adult dose of BONTRIL is: BONTRIL 50 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE and BONTRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is classified as Category A/B. First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine bl. BONTRIL is classified as Category C. BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.